CMMB News and Press, Chemomab Therapeutics Ltd. From 05/26/22

The following slide deck was published by Chemomab Therapeutics Ltd. in conjunction with this event. For further details see: Chemomab Therapeutics (CMMB) Investor Presentation - Slideshow

Chemomab Therapeutics to Participate in H.C. Wainwright Global Investment Conference PR Newswire TEL AVIV, Israel , May 18, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd . (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on ...

Chemomab Therapeutics Ltd. (CMMB) Q1 2022 Earnings Conference Call May 11, 2022 08:00 AM ET Company Participants Barbara Lindheim - Consulting Vice President Investor & Public Relations Dale Pfost - Chairman & CEO David Weiner - Interim CMO Don Marvin - CFO, COO & EVP Adi Mor - Co...

Chemomab Therapeutics - ADR press release (NASDAQ:CMMB): Q1 GAAP EPS of -$0.022. Cash and cash equivalents were $57.5 million as of March 31, 2022, compared to $61.2 million as of December 31, 2021 For further details see: Chemomab Therapeutics - ADR GAAP EPS of -$0.022

Chemomab Therapeutics Announces First Quarter 2022 Financial Results and Provides Corporate Update PR Newswire -- Company to Host Conference Call for Investors Today, May 12 at 8:00 am ET -- TEL AVIV, Israel , May 12 , 2022 /PRNewswire...

Chemomab Therapeutics to Report First Quarter 2022 Financial Results and Provide a Business Update PR Newswire TEL AVIV, Israel , May 4, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd . (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology compan...

Chemomab Therapeutics Ltd. (NASDAQ:CMMB) traded today at a new 52-week high of $89.90. So far today approximately 5.7 million shares have been exchanged, as compared to an average 30-day volume of 74,000 shares. Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on t...

Chemomab Therapeutics to Participate in Cantor Fitzgerald Rare Orphan Disease Summit PR Newswire TEL AVIV, Israel , March 23, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd . (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused o...

Chemomab Reports on Two Scientific Presentations that Support the Potential Therapeutic Utility of CM-101 in Systemic Sclerosis PR Newswire —Translational Study Data Presented at 7 th Systemic Sclerosis World Congress Confirms CCL24 is Elevated in Diffu...

Gainers: Kala Pharmaceuticals (NASDAQ:KALA) +20%. Natera (NASDAQ:NTRA) +17%. Chemomab Therapeutics (NASDAQ:CMMB) +13%. Selecta Biosciences (NASDAQ:SELB) +11%. Longeveron (NASDAQ:LGVN) +7%. Losers: Sunshine Biopharma (NASDAQ:SBFM) -32%. My...